Ionis Pharmaceuticals Inc (IONS) Actualités

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor...

Form 4 - Statement of changes in beneficial ownership of securities

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

– Data also show significant and clinically meaningful improvements in quality-of-life measures in new analyses from Phase 3 and Phase 2 clinical...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Ionis reports fourth quarter and full year 2024 financial results

- First independent launch underway following TRYNGOLZATM approval - - Second independent launch on track with donidalorsen PDUFA August 21...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Ionis to hold fourth quarter and full year 2024 financial results webcast

Webcast scheduled for Wednesday, February 19 at 11:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will...

Form 144/A - Report of proposed sale of securities: [Amend]

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities